4th ESO-ESMO Breast Cancer in Young Women International Conference (BCY4)

Chair: O. Pagani, CH
Scientific committee: F. Cardoso, PT - N. Harbeck, DE - S. Paluch-Shimon, IL - A. Partridge, US - F. Peccatori, IT - E. Senkus, PL - Y. Wengström, SE
 
 
Breast cancer in young women is a complex disease, occurring when these women are at the peak of their reproductive years, family life and careers. Being a somewhat rare disease the optimal management of these patients is based on scientific data derived from clinical trials mostly conducted on older women. Many aspects of breast cancer in young women are therefore poorly understood (e.g. etiology and biology among others) and research is much needed in this field. In addition, young women have many years ahead of them to suffer the long-term effects of treatment and specific survivorship issues (fertility and job among others). This fourth conference is a new opportunity for the latest updates on this field and a platform for generating future research concepts and collaborations. It will cover epidemiology, molecular biology, genetics, pathology, surgery, radiotherapy, systemic therapy, survivorship issues in young women with breast cancer.
It will also include a Consensus Session that will form the basis for a Consensus Guidelines manuscript to be published after the Conference.

LEARNING OBJECTIVES
• In depth learning and update of the scientific and clinical aspects of breast cancer in young women
• Highlight the importance of multi-disciplinary management and discuss difficult clinical cases
• Focus on clinical research priorities and future perspectives, involving patients’ advocates in setting the agenda
• Participate in the discussion of consensus guidelines

MAIN TOPICS
• Epidemiology of early and advanced disease
• Biology
• Hereditary breast cancer
• Diagnostic tools and challenges
• Loco-regional therapy
• Systemic therapy
• Psychosocial aspects and survivorship

The Conference is an ESO-ESMO joint event.

Held under the patronage of

FACULTY
O. Abulkhair, King Abdulaziz Medical City for National Guard, Riyadh, SA
L. Audergon, Comano, CH
H.A. Azim Jr., American University of Beirut, Beirut, LB
L. Baider, Assuta Medical Center, Tel-Aviv, IL
G. Bianchi Micheli, Southern Switzerland Breast Center (CSSI), Viganello, Lugano, CH
S. Bober, Dana-Farber Cancer Institute, Boston, US
C. Canonica, Bellinzona and Valleys Regional Hospital, Bellinzona, CH
F. Cardoso, Champalimaud Clinical Center, Lisbon, PT
M.J. Cardoso, Champalimaud Clinical Center, Lisbon, PT
S. Cima, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
R. Condorelli, Locarno Regional Hospital, Locarno, CH
M. Conti Beltraminelli, Italian Hospital, Viganello, Lugano, CH
G. Curigliano, European Institute of Oncology, Milan, IT
S. Di Lascio, Mendrisio Regional Hospital, Mendrisio, CH
N.S. El Saghir, American University of Beirut Medical Center, Beirut, LB
S. Gal, Jerusalem, IL
J. Garber, Dana Farber Cancer Institute Boston, US
K. Gelmon, BC Cancer Agency, Vancouver, CA
A. Gorini, Milan University, Milan, IT
R. Graffeo, Oncology Institute of Southern Switzerland (IOSI), Lugano, CH
S. Han, UZ Leuven, Lauven, BE
N. Harbeck, University of Munich (LMU), Munich, DE
B. Kaufman, Sheba Medical Center, Ramat Gan, IL
M. Lambertini, Institut Jules Bordet, Brussels, BE
K. Lång, Lund University, Malmö, SE
F. Meani, Lugano Regional Hospital, Lugano, CH
J. Merschdorf, Young Survival Coalition, New York, US
C. O'Brien, St James's Hospital, Dublin, IE
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Bellizona, CH
S. Paluch-Shimon, Shani Shaare Zedek Medical Centre, Jerusalem, IL
A.H. Partridge, Dana-Farber Cancer Institute, Boston, US
F.A. Peccatori, European Institute of Oncology, Milan, IT
P. Poortmans, Institut Curie, Paris, FR
G. Pravettoni, European Institute of Oncology, Milan, IT
G. Pruneri, National Cancer Institute - Foundation IRCCS, Milan, IT
A. Richetti, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
K. Rosenzweig, Kfar Saba, IL
A. Santi, Locarno Regional Hospital, Locarno, CH
M. Schilstra, NL
E. Senkus, Medical University of Gdansk, Gdansk, PL
B. Sirohi, Barts Health NHS Trust, London, UK
T. Spanic, Europa Donna Slovenia, Ljubljana, SI
S. Spitz, EuropaDonna, Vienna, AT
V. Stearns, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US
M. Taborelli, Italian Hospital, Viganello, Lugano, CH
M. Valli, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
I. Vaz-Luis, Gustave Roussy Institute, Villejuif, FR
V.A. Vitale, Southern Switzerland Breast Center (CSSI), Viganello, Lugano, CH
Y. Wengström, Karolinska Institutet & Cancer Theme, Karolinska University Hospital, Huddinge, SE
J. Winterling, Karolinska University Hospital, Stockholm, SE
S. Zehbe, Bellinzona and Valleys Regional Hospital, Bellinzona, CH
S. Zuckerman, Shaare Zedek Medical Center, Jerusalem, IL

ORGANISING SECRETARIAT

Organisation and Programme
Francesca Marangoni (1)
email: fmarangoni@eso.net
phone: +39 02 85464525

Registrations and Abstracts
Alice Ciocchini (1)
email: aciocchini@eso.net
phone: +39 02 85464529

Sponsorship and travel grants
Luis Carvalho (2)
email: lcarvalho@eso.net
phone: +41 91 8200958

Social Media
Corinne Hall (1)
email: chall@eso.net
phone: +39 02 85464522

Communication
Gabriele Maggini
email: gmaggini@eso.net
phone: +41 91 8200955

(1) European School of Oncology, Via Turati 29, 20123 Milan, Italy
(2) European School of Oncology, Piazza Indipendenza 2, 6500 Bellinzona, Switzerland

VENUE
Palazzo dei Congressi Lugano
Piazza Indipendenza 4
6900 Lugano
Switzerland
Website: http://www.luganoconventions.com/en/13/default.aspx

OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.

INSURANCE
The organisers bear no responsibility for ontoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.

ABSTRACT BOOK
An abstract book will be published as supplement to The Breast and will contain abstracts of the invited lecturers and those submitted by the participants that have been accepted for oral or poster presentation or for publication only. The best abstracts have been selected and proposed for oral presentation (Free registration will be granted to the first author of the selected abstracts). Oral presentations will be scheduled on 8 October while poster session will be scheduled on 7 October.

CME ACCREDITATION CERTIFICATES
Participants will be issued a certificate of attendance.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 16 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
The programme was furthermore awarded with 14 cat. 1 ESMO-MORA points.

WI-FI ACCESS
Free Wi-Fi internet access in all areas of the BCY4 venue is available.
WLAN SSID: PalazzoCongressi
Password: Luga2018

FILMING, AUDIOGTAPING AND PHOTOGRAPHS
Please note that capturing contents of the sessions is prohibited.

REGISTRATION DESKS, OPENING HOURS
Saturday, 6 October (10:00 - 19:00)
Sunday, 7 October (8:00 - 19:20)
Monday, 8 October (8:00 - 14:00)

EXHIBITION, OPENING HOURS
Saturday, 6 October (12:00 - 19:00)
Sunday, 7 October (8:00 - 19:10)
Monday, 8 October (8:00 - 13:00)

FACULTY AND PANEL MEMBERS
Members of the faculty are invited to refer to the Faculty Room (first floor).

TRAVEL GRANTS
Travel grants have been made available on a competitive basis.
ESO is particularly grateful to the ABC Global Alliance, Amgen and the Breast Cancer Research Foundation for having provided grants to support the participation of several participants.

                


SPONSORED SATELLITE SYMPOSIA

6 October 2018 (18:00 - 19:00) Roche satellite symposium  NAVIGATING HER2-POSITIVE eBC TREATMENTS Chair: A. Bodmer, CH Neoadjuvant treatment of HER2-positive early breast cancer K. Dedes, CH Adjuvant treatment of HER2-positive early breast cancer A. Bodmer, CH Clinical experience in the adjuvant treatment of HER2-positive early breast cancer A. Stravodimou, CH Symposium faculty: A. Bodmer, Hôpitaux Universitaires de Genève (HUG) K. Dedes, Universitäts Spital Zürich (USZ) A. Stravodimou, Centre Hospitalier Universitaire Vaudois (CHUV)

7 October 2018, (18:20 - 19:20) - Ipsen satellite symposium THE GLOBALE CARE OF YOUNG WOMEN WITH BREAST CANCER: TAKE CARE FROM CURE TO CARE Introduction M. Cazzaniga, IT Cardiovascular health M. Destro, IT Lifestyle Coach Yourself M. Bandera, IT Bone health A. Lania, IT Bone health: physical exercise, role in the control of osteo - articolar symtomps G. Biasi, IT Conclusion and take home messages M. Cazzaniga, IT Symposium faculty: M. Cazzaniga, Direttore UOC Centro di ricerca Fase 1, ASST Monza M. Destro, Direttore Medicina Generale 1 Treviglio M. Bandera, Libero professionista, IT A. Lania, Responsabile di Unità Operativa Endocrinologia, Dipartimento di Medicina Interna, Humanitas G. Biasi, Dipartimento di Prevenzione - Azienda ULSS n. 2 Marca Trevigiana - UOC di Medicina dello Sport e dell'Esercizio Fisico

BCY CONFERENCE AND CONSENSUS GUIDELINES
Breast Cancer in Young Women Conference (BCY1)
8-10 November 2012
The guidelines are published in The Breast 23 (2014) 209-220

2nd Breast Cancer in Young Women Conference (BCY2)
4-5 November 2014
The guidelines are published in The Breast 26 (2016) 87-99

3rd ESO-ESMO Breast Cancer in Young Women International Conference (BCY3)
10-12 November 2016
The guidelines are published in The Breast 26 (2017), Volume 35, pages 203–217

ACKNOWLEDMENTS
Session 5 on Fertility and Pregnancy is supported by Dana-Farber Cancer Institute while the Nursing session is held in collaboration with EONS.

SPONSORS
ESO wishes to express its appreciation to the following sponsors for having granted their participation and support to BCY4:

A/V RECORDING DURING THE CONFERENCE IS PROHIBITED

POSTER SESSION
A prefix has been added to the abstract number to identify the type of presentation or acceptance:

OR: Abstract accepted for oral presentation.
BP: Abstracts identified as best posters.
PO: Abstracts accepted for poster presentations.

OR52 Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. Cristofanilli Massimo, USA

OR53 A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. Yerushalmi Rinat, Israel

OR92 Understanding surgical decision-making in newly diagnosed young women with early-stage breast cancer.
Rosenberg Shoshana, USA

OR93 Patient-reported outcomes and factors associated with early discontinuation of adjuvant endocrine therapy in
premenopausal women with breast cancer. Smith Karen, USA

BP54 Differences in breast cancer stage at diagnosis by ethnicity, insurance status and family income in young woman in the United States. Franzoi Maria Alice, Brazil

PO45 Challenges in India about breast cancer & breast reconstruction. Maudgal Shubha, India

PO46 Better palliative care for terminal cancer patients in rural India - an NGO based approach. Mandal Nabanita, India

PO47 Breast health awareness in an Arabic culture: a qualitative exploration. Madkhali Norah, Saudi Arabia

PO48 Know your legal rights: education for young women diagnosed with breast cancer. Merschdorf Jennifer, USA

PO49 Knowledge, attitude and preventive measures for breast cancer among health care professionals at Bolan Medical Complex Hospital Quetta. Jogezai Pari Gul, Pakistan

PO51 Co-Survivors: a continuing need for education and support. Merschdorf Jennifer, USA

PO55 Incidence and prognosis of pregnancy-associated breast cancer: time-trends study from the nationwide Korean breast cancer registry database. Bae Soo Youn, South Korea

PO56 Localized triple negative breast cancer in young patients. Oualla Karima, Marocco

PO57 Analysis of the comparative characteristics of various neoadjuvant chemotherapy regimens for breast cancer patients associated with a BRCA1 mutation. Gigolaeva Larisa, Russian Federation

PO58 Prognostic factors of breast cancer in Algerian young women ≤ 35 years: about 578 cases. Guendouz Hamida, Algeria

PO59 Comparison of outcomes in young and very young women with breast cancer. Yadav Budhi Singh, India

PO60 Neoadjuvant chemotherapy treatment of breast cancer in young women in Albania. Malaj Besmira, Albania

PO61 The statistical interpretation of SBR grade severity and Ki-67 in young women with breast cancer in Morocco.
Akhouayri Laila, Marocco

PO62 Breast cancer in young women and coverage with mass screening. Ninashvili Nanuli, Georgia

PO63 Adjuvant radiation therapy in young breast cancer patients: current state of the art and evidence-based algorithm. Meattini Icro, Italy

PO64 Correlation of imaging features with clinicopathological features and immunohistochemical subtypes in young breast cancer women. Mehmood Tahir, Pakistan

PO65 Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME MBC cohort. Frank Sophie, France

PO66 Prognostic factors of disease progression in young breast cancer patients. Kozma Elvisa, Albania

PO67 Inadequate treatment still a major problem for Indonesian young age breast cancer patients: a single institutional experience. Salim Adrian, Indonesia

PO68 Adjuvant chemotherapy in young breast cancer patients with endrocrine receptor (ER) disease. Luz Paulo, Portugal

PO69 Breast cancer in young women: understanding our reality. da Silva Dias David, Portugal

PO70 Clinicopathological features of young women (≤39 years old) with invasive breast cancer. Utsumi Toshiaki, Japan

PO71 Modern chemotherapy use among young women with early-stage ER+/HER2- breast cancer. Poorvu Philip, USA

PO72 The effect of symbiotic gut bacterial differences in young breast cancer patients. An Jeongshin, South Korea

PO73 Heterogeneity of triple negative breast cancer occurring in young women: an immunohistochemical analysis.
Tsvetkova Vassilena, Italy

PO74 Pregnancy-associated breast cancer (PABC) in young Tunisian women: aggressive features and poor outcome.
Mejri Turki Nesrine, Tunisia

PO75 Differences in histological markers expression in early stage breast cancer in young women ( 40 years) according to Nottingham Prognostic Index classification. Mejri Turki Nesrine, Tunisia

PO76 A postpartum diagnosis increases risk for and determines an altered profile of metastasis in young women’s breast cancer. Borges Virginia, USA

PO94 Knowledge and health beliefs about breast cancer screening among rural Palestinian women: pilot study.
Saca-Hazboun Hanan, Palestinian Terrirories

PO95 The impact of chemotherapy and radiotherapy for breast cancer on cognition and functional performance. Potter Ann Marie, USA

PO96 Only a few young patients aged 40 years with ‘high-risk’ breast cancer preserved fertility; report from actual survey in a Japanese cancer hospital. Kataoka Akemi, Japan

PO97 Young breast cancer survivors and insomnia: a multicenter Swiss snapshot. Rossi Lorenzo, Switzerland

PO98 Treatment satisfaction in young women receiving palbociclib combination therapies for advanced/metastatic breast cancer in multiple countries globally. Iyer Shrividya, USA

PO99 Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/ HER2- subpopulation. Hurvitz Sara A., USA

PO100 Clinical outcomes, treatment patterns and health resource utilization (HRU) in triple negative metastatic breast cancer (mTNBC): a comparison between younger and older patients (pts) with germline BRCA mutation (gBRCAm). Quek Ruben G.W., USA

PO101 A systemic review of information requirements of young women with breast cancer undergoing mastectomy or breast conserving surgery. Mehmood Tahir, Pakistan

PO102 Evaluation of depression and anxiety in young women with metastatic breast cancer. Mehmood Tahir, Pakistan

PO103 Literature review of partner support and anxiety in young women with breast cancer. Mehmood Tahir, Pakistan

PO104 Characterization of young Mexican patients with breast cancer who underwent oocyte/embryo preservation. Villarreal-Garza Cynthia Mayte, Mexico

PO105 Follow-up status, patient retention and data collection of the "Joven & Fuerte" cohort for young women with breast cancer in Mexico. Villarreal Garza Cynthia Mayte, Mexico

PO106 The special concerns of young breast cancer patients before neo/adjuvant chemotherapy. Pogoda Katarzyna, Poland

PO108 Fertility preservation provision for breast cancer patients in England - a postcode lottery. Dash Isabella, UK